Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells
© Furukawa et al.; licensee BioMed Central Ltd. 2012
Received: 10 August 2012
Accepted: 5 December 2012
Published: 10 December 2012
Pancreatic cancer is characterized by constitutive activation of mitogen-activated protein kinase (MAPK). Activation of MAPK is associated with the upregulation of genes implicated in the proliferation and survival of pancreatic cancer cells. We hypothesized that knockdown of these MAPK-associated molecules could produce notable anticancer phenotypes.
A RNA interference-mediated knockdown screening of 78 MAPK-associated molecules previously identified was performed to find molecules specifically associated with proliferation of pancreatic cancer cells in vitro. Expression of an identified molecule in pancreatic cancer tissues was examined by immunohistochemistry. In vivo tumorigenicity of cancer cells with stable knockdown of the molecule was assayed by using xenograft models. Flow cytometry and live cell imaging were employed to assess an association of the molecule with cell cycle.
The knockdown screening revealed that knockdown of SON, the gene encoding SON, which is a large serine/arginine-rich protein involved in RNA processing, substantially suppressed pancreatic cancer cell proliferation and survival in vitro and tumorigenicity in vivo. SON expression was higher in ductal adenocarcinomas than in cells of normal ducts and precursor lesions in pancreatic cancer tissues. Knockdown of SON induced G2/M arrest and apoptosis in cultured cancer cells. The suppressive effect of SON knockdown on proliferation was less pronounced in cultured normal duct epithelial cells. SON formed nuclear speckles in the interphase of the cell cycle and dispersed in the cytoplasm during mitosis. Live cell imaging showed that SON diffusely dispersed in the early mitotic phase, accumulated in some foci in the cytoplasm in the late mitotic phase, and gradually reassembled into speckles after mitosis.
These results indicate that SON plays a critical role in the proliferation, survival, and tumorigenicity of pancreatic cancer cells, suggesting that SON is a novel therapeutic molecular target for pancreatic cancer.
KeywordsSON MAPK RNA interference Speckle Cell cycle
Aurora kinase A
Aurora kinase B
Centromere protein A
Dual specificity phosphatase 6
Epstein-Barr virus nuclear antigen 1-binding protein 2
Enhanced green fluorescence protein
Golgi transport 1A
Histone H3 lysine 4
Kinesin family member 11
Mitogen-activated protein kinase
Neural precursor cell expressed, developmentally down-regulated 4-like, an E3 ubiquitin protein ligase
Pancreatic intraepithelial neoplasia
Short hairpin RNA
Short interfering RNA
A homologue of Tpx2 of Xenopus
WD repeat domain 5.
Pancreatic cancer is a leading cause of cancer-related deaths [1, 2]. Despite advancements in diagnostic and therapeutic modalities, the 5-year survival rate of patients with pancreatic cancer is less than 10% . This poor prognosis elicits an urgent need for the development of effective diagnostic and therapeutic measures to improve patient survival. Molecular medicine may be able to fulfill this need, as exemplified by imatinib in the treatment of chronic myeloid leukemia . Pancreatic cancer is characterized by constitutive activation of mitogen-activated protein kinase (MAPK), due to gain-of-function mutations in KRAS or BRAF and loss-of-function of dual specificity phosphatase 6 (DUSP6) [5–7]. Active MAPK translocates to the nucleus, activates transcription factors, and induces the expression of a variety of genes . In a previous study, we screened the genome for downstream targets of MAPK and identified 78 molecules specifically associated with MAPK activity in pancreatic cancer cells . These MAPK-associated molecules include molecules implicated in DNA replication, RNA editing, spindle formation, mitosis, signal transduction, and membrane trafficking. These biological processes play critical roles in the survival, maintenance, and proliferation of pancreatic cancer cells. We hypothesized that molecular targeting of these MAPK-associated molecules could result in notable anticancer phenotypes, as we previously observed by targeting AURKA[9, 10]. In this study, we performed a systematic knockdown screening of MAPK-associated molecules in pancreatic cancer cells.
Knockdown screening of MAPK-modulated genes in pancreatic cancer cells
Knockdown of SON attenuates proliferation in vitro, considerably in pancreatic cancer cells but less remarkably in normal phenotype cells
Stable knockdown of SON reduces the survival of pancreatic cancer cells in vitro
We next constructed a vector expressing short hairpin RNA (shRNA) identical to the SON siRNA when processed. We examined the effect of stable knockdown of SON on the survival of pancreatic cancer cells in vitro using a colony formation assay. We found that stable knockdown of SON strongly attenuated the survival of cancer cells, even in PCI-35 cells, in which transient transfection of siRNA targeting SON modestly suppressed proliferation (Figure 2C).
SON is overexpressed in pancreatic ductal adenocarcinomas
Expression of SON in ductal lesions evaluated by immunohistochemistry
Total number of lesions
Knockdown of SON retards the tumorigenicity of pancreatic cancer cells in vivo
Knockdown of SON induces cell cycle arrest and apoptosis
To determine the mechanism by which SON knockdown suppresses the proliferation and survival of pancreatic cancer cells, the DNA content of siRNA-transfected MIA PaCa-2 and PCI-35 cells was measured by flow cytometry, and the cell cycle was assessed. Knockdown of SON increased the fraction of cells in G2/M and sub-G1, indicating that the cells were in G2/M arrest and apoptosis (Figure 4B).
SON shuttles between the nucleus and cytoplasm depending on the cell cycle
In this study, among many genes associated with MAPK, we found that knockdown of SON remarkably suppressed the proliferation, survival, and tumor formation of pancreatic cancer cells. The suppressive effect was less pronounced in normally phenotypic ductal cells. In primary pancreatic cancer tissues, SON was overexpressed in ductal adenocarcinomas compared with normal duct cells and PanINs. Knockdown of SON induced G2/M arrest and apoptosis. SON shuttled between the nucleus and cytoplasm depending on the phase of cell cycle. These results indicate that SON plays a crucial role in the proliferation, survival, and tumorigenicity of pancreatic cancer cells, thus suggesting that this molecule could be a prime therapeutic molecular target for pancreatic cancer.
Our investigation showed that knockdown of MAPK-associated molecules suppressed the proliferation of pancreatic cancer cells in vitro to variable degrees. We found that knockdown of AURKB, CENPA, EBNA1BP2, GOLT1A, KIF11, NEDD4L, SON, TPX2, or WDR5 strongly suppressed the proliferation. AURKB encodes aurora kinase B (AURKB), which is involved in chromosome segregation and cytokinesis during mitosis . CENPA encodes centromere protein A (CENPA), which, by functioning as a replacement for histone H3 in centromeric nucleosomes, plays an essential role in kinetochore formation and functions in cellular mitosis . EBNA1BP2 encodes a ribonucleoprotein, Epstein-Barr virus nuclear antigen 1-binding protein 2 (EBNA1BP2), which serves as a scaffold for ribosome biogenesis . GOLT1A encodes Golgi transport 1A (GOLT1A), which functions as a transporter on the Golgi membrane . KIF11 encodes a microtubule-dependent motor protein, kinesin family member 11 (KIF11), which plays a critical role in chromosome positioning during mitosis . NEDD4L encodes neural precursor cell expressed, developmentally down-regulated 4-like, an E3 ubiquitin protein ligase (NEDD4L) that plays a role in polyubiquitination and proteasomal destruction of SMAD2/3 . TPX2 encodes a homologue of Tpx2 of Xenopus (TPX2), a binding partner of aurora kinase A (AURKA) that plays a role in microtubule spindle formation . WDR5 encodes WD repeat domain 5 (WDR5), which binds methylated histone H3 lysine 4 (H3K4) and is required for recruiting H3K4 methyltransferase . Among these, AURKB, CENPA, KIF11, and TPX2 are involved in functions of the microtubule spindles and kinetochores, which are considered essential for cell mitosis. Because we screened by assaying the effects of knockdown of the MAPK-associated genes on in vitro proliferation of pancreatic cancer cells, molecules associated with the microtubules and kinetochores might be selectively represented in our screening. Interestingly, these microtubule kinetochore-associated molecules have already been studied as molecular targets in various cancers [22–25]. Nevertheless, of these MAPK-associated molecules, we found that knockdown of SON most remarkably suppressed proliferation, which led us to investigate SON in detail as a candidate molecular target.
SON encodes SON, a large protein harboring a serine or arginine-rich domain. It was first cloned as a gene encoding a protein with DNA-binding activity. However, subsequently, it turned out to be a nuclear speckle protein involved in RNA processing and required for proper and efficient splicing of pre-mRNAs [26–30]. In our study, knockdown of SON attenuated the proliferation, survival, and tumorigenicity of pancreatic cancer cells. These suppressive effects were attributable to cell cycle arrest at the G2/M phase and apoptosis induced by depletion of SON. The association between the depletion of SON and G2/M arrest has been reported to be associated with impairment of spindle pole separation, microtubule dynamics, and genome integrity due to inadequate RNA splicing of a specific set of cell cycle-related genes with weak splice sites, i.e., splice sites without the conserved sequence .
Pancreatic cancer cells were more susceptible to depletion of SON than normally phenotypic cells. This may be due to rapid progression through the cell cycle in cancer cells, which results in exaggerated dependence on SON to maintain efficient RNA processing of the cell cycle-related genes. This interpretation could be endorsed by the overexpression of SON we found in most ductal adenocarcinomas, compared with normal ductal cells or precursor lesions, which suggests that adenocarcinoma cells depend on SON more strongly than normal ductal cells and precursor lesions to maintain their phenotypes. These results suggest that depletion of SON may specifically lead to an anticancer phenotype. SON overexpression is purportedly due to the constitutive activation of MAPK in ductal adenocarcinoma; however, other possible causes, such as gene amplification or aberrations in protein turnover, cannot be ruled out and will be a subject of further study.
The dynamics of SON distribution during the cell cycle is not well known. We performed live-cell imaging of cells expressing EGFP-SON and observed that SON dispersed in the cytoplasm during early mitotic phase formed small foci in the cytoplasm in the late mitotic phase, and gradually redistributed as speckles in the nucleus as foci in the cytoplasm faded. The cytoplasmic small foci are supposed to be mitotic interchromatin granules that correspond to accumulations of nuclear speckle proteins in the cytoplasm in the late mitotic phase [31, 32]. These dynamics seem similar to the dynamics of another speckle protein, SF2, and are consistent with the idea that SON plays a role in the appropriate organization of RNA splicing factors [29, 33, 34].
The knockdown of SON by RNA interference showed sufficient anti-cancer phenotypes experimentally. For the RNA interference, vector-mediated stable transduction appeared to be more effective than oligonucleotide-based transient transduction as shown in Figure 2. Although the stable knockdown of SON by RNA interference could be an efficient molecular therapy for pancreatic cancer, the lack of a conventional method for tissue-specific, stable delivery of short, double-stranded RNA could limit the use of this approach in clinical therapeutics. Indeed, the use of RNA interference in clinical practice is generally not warranted. Recently, however, systemic delivery of siRNA combined with a special nanoparticle successfully knocked down a target gene in melanoma in a clinical trial . The use of such a technique to attempt specific knockdown of SON in pancreatic cancer cells in a clinical model is worth trying and is an issue to be resolved in a future study. The results of this study also suggest that development of a molecule-oriented chemical substance against SON as therapy for pancreatic cancer is warranted.
This study indicates that SON is overexpressed and plays a critical role in the proliferation, survival, and tumorigenicity of pancreatic cancer cells, suggesting that SON is a novel therapeutic molecular target for pancreatic cancer.
Human pancreatic cancer cell lines, MIA PaCa-2 and PCI-35, and the human embryonic kidney cell line 293 were obtained and cultured as previously described [7, 9]. The immortalized human pancreatic duct-epithelial cell line, HPDE, was kindly provided by Dr. MS Tsao (Princess Margaret Hospital and Ontario Cancer Institute, Toronto, ON) and cultured as previously described .
Transfection of siRNA and cell proliferation assay
siRNAs targeting each downstream MAPK-associated molecule were custom designed and manufactured (RNAi Co. Ltd., Tokyo, Japan) (Additional file 1: Table S1). Cells were seeded at 5 × 103 cells/well in 96-well plates with 100 μL of appropriate culture medium and incubated at 37°C with 5% CO2 for 24 hours. Then, the medium was replaced with OPTI-MEM (Life Technologies, Carlsbad, CA), and the cells were transfected with siRNA at 10 nM with Oligofectamine (Life Technologies) according to the manufacturer’s recommendations. After 4 hours of incubation, the transfection reagent was replaced with the appropriate culture medium. A colorimetric cell proliferation assay—3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay—was performed daily for 5 days as previously described .
Colony formation assay with shRNA vectors
pSUPER vector (Oligoengine, Seattle, WA) was used for the construction of vectors expressing shRNAs by cloning the oligonucleotides 5′-GATCCCCGCATCTAGACGTTCTATGATTCAAGAGATCATAGAACGTCTAGATGCTTTTTA-3′ and 5′-AGCTTAAAAAGCATCTAGACGTTCTATGATCTCTTGAATCATAGAACGTCTAGATGCGGG-3′ to target SON (shRNA-SON), and 5′-GATCCCCGTACCGCACGTCATTCGTATTCAAGAGATACGAATGACGTGCGGTACTTTTTA-3′ and 5′-AGCTTAAAAAGTACCGCACGTCATTCGTATCTCTTGAATACGAATGACGTGCGGTACGGG-3′ to serve as a control harboring a nonspecific sequence against the human genome (shRNA-Nons) according to the manufacturer’s instructions. MIA PaCa-2 and PCI-35 cells were seeded at 1 × 105 cells/well in 6-well plates and incubated for 24 hours at 37°C with 5% CO2. The shRNA-SON vector or shRNA-Nons vector were transfected into the cells with LipofectamineTM reagent (Life Technologies) according to the manufacturer’s recommendations. The cells were dissociated with trypsin 48 hours after transfection and reseeded in three 10-cm tissue-culture dishes, containing the appropriate culture medium supplemented with 10% FBS and G418 (Life Technologies) at 400 μg/mL for PCI-35 and 500 μg/mL for MIA PaCa-2. After 3 weeks, the cells were fixed with 10% formalin solution and stained with hematoxylin. The number of colonies was assessed with the COLONY program (Fujifilm Co. Ltd., Tokyo, Japan).
Thirty-four formalin-fixed, paraffin-embedded tissues of pancreatic ductal adenocarcinoma that were surgically resected during 2006 and 2007 at Tokyo Women’s Medical University Hospital were studied. Indirect immunohistochemical staining was performed as previously described  by using a polyclonal anti-SON antibody (1:1200 dilution, Sigma, St. Louis, MO), a secondary antibody against rabbit immunoglobulin (Nichirei, Tokyo, Japan), and streptavidin solution (Nichirei). Use of the archival pathological tissues was approved by the ethics committee of Tokyo Women’s Medical University. Immunohistochemical results were evaluated among ductal lesions classified into adenocarcinoma, PanIN, or normal duct by scoring intensities of staining into 1, weak; 2, moderate; and 3, strong by comparing with normal ductal cells that showed weak staining or acinar cells that showed moderate staining. The scores were statistically analyzed by ANOVA by using PASW Statistics software (IBM Japan, Tokyo, Japan).
Quantitative real-time polymerase chain reaction assay
The TaqMan Gene Expression Assay and a 7500 Real-time PCR system (Life Technologies) were used to analyze the transcriptional expression of SON by using the absolute quantitative assay according to the manufacturer’s instructions. The expression of SON was assessed relative to the endogenous expression of GAPDH.
In vivo tumorigenicity assay
Pancreatic cancer cells stably transfected with shRNA vectors were isolated by cloning the surviving cells from the colony formation assay. These clones, in 50% matrigel/culture medium without FBS, were inoculated into the subcutis of BALB/c nude mice (Clea Japan Inc., Tokyo, Japan). Tumorigenicity was monitored weekly, and the tumor volume was calculated using the following formula: V = D × d2 × 0.4 (V, tumor volume; D, largest dimension; d, smallest dimension).
Flow cytometric analyses for cell cycle and apoptosis were performed as previously described .
Construction of the EGFP-SON vector
An expression vector containing the full coding sequence of SON cDNA (NM_138927) was constructed by assembling amplified products using KOD Plus DNA Polymerase and its specific buffer (TOYOBO, Osaka, Japan), appropriate paired primers, and pooled cDNA obtained from a fetal brain cDNA library (Stratagene/Agilent Technologies Inc., Santa Clara, CA) as follows. Paired primers used for amplification of cDNA fragments were C51, 5′-TTTAAGCTTATGGCGACCAACATCGAGCAG-3′ (melting temperature [Tm], 58°C) and C12, 5′-TAAGGGTGTTCTTGATCGCC-3′ (Tm, 52°C); C7, 5′-AGCCGCCGGAGAAGATCAAGG-3′ (Tm, 59°C) and C10, 5′-CAGGCTCTGAGGGCAAATTG-3′ (Tm, 53°C); and C5, 5′-TAAACTCAGTGAACCCAAACC-3′ (Tm, 50°C) and C52, 5′-TTTGGTACCTCAATACCTATTCAAGAAAAACATAC-3′ (Tm 48°C). Products amplified by PCR were sequentially cloned into the pFLAG-CMV-4 vector (Sigma, St. Louis, MO) at Hin dIII-Eco RI-Kpn I sites to obtain pFLAG-SON. The pEGFP-C2 vector (Clontech, Mountain View, CA) was modified by fill-in of its Xho I site to adjust the reading frame. The coding region of SON cDNA was prepared from pFLAG-SON by digestion with Hin dIII and Kpn I for the 3′ fragment and Hin dIII for the 5′ fragment. These fragments were sequentially cloned into the modified pEGFP-C2 vector at Hin dIII and Kpn I sites to obtain the pEGFP-SON vector. DNA sequences were confirmed by using BigDye® Terminator and a 3130x Genetic analyzer (Life Technologies).
Denatured total cell lysate was separated in a 5–15% polyacrylamide gel and blotted onto a polyvinylidene fluoride membrane by using an XV Pantera MP System (DRC Co., Ltd. Tokyo, Japan) according to the manufacturer’s recommendations. The blotted membrane was probed with anti-SON antibody (Sigma), anti-beta actin antibody (Sigma), or anti-EGFP antibody (Clontech). Horseradish peroxidase-conjugated anti-rabbit or anti-mouse immunoglobulin antibodies (GE Healthcare UK Ltd., Buckinghamshire, UK) were used for the secondary antibody reaction. Blocking conditions and concentrations of antibodies were determined according to the manufacturers’ recommendations. Signals were visualized by reaction with ECL Detection Reagent (GE Healthcare UK Ltd.) and captured digitally by using an LAS 4000 Mini (Fujifilm Co. Ltd.) or by autoradiography. Intensities of bands were measured digitally using Image Gauge software (Fujifilm Co. Ltd.).
Laser scanning fluorescence imaging
The pEGFP-SON vector was transfected into 293 cells using Lipofectamine Plus (Life Technologies) according to the manufacturer’s recommendations. The transfected cells were incubated with Eagle’s Minimum Essential Medium (Sigma) supplemented with 10% FBS and 400 μg/mL G418. Stably transfected clones were obtained by cloning surviving cells using a cylinder cup. The isolated clones were seeded in a glass-bottom dish and incubated for 24 hours. The cells were incubated with a medium supplemented with 0.1 μg/mL Hoechst 33342 (Life Technologies) for 30 minutes. The medium was then replaced with fresh growth medium and examined under a confocal laser scanning microscope (LSM5, Carl-Zeiss Microimaging GmbH, Goettingen, Germany). Time-lapse images were obtained for 2 layers at 0- and 5-μm depth with 10-minute intervals over a total of 230 minutes.
Student’s t-test was applied to analyze statistical differences using Statview 5.0 software (SAS Institute Inc., Cary, NC, USA). P values of <0.05 were considered statistically significant.
We thank Dr. Ming S. Tsao at Princess Margaret Hospital and Ontario Cancer Institute, Toronto, ON, for providing HPDE. This study was supported by Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science; Program for Promoting the Establishment of Strategic Research Centers, Special Coordination Funds for Promoting Science and Technology, Ministry of Education, Culture, Sports, Science and Technology (MEXT); and MEXT-Supported Program for the Strategic Research Foundation at Private Universities.
- Cancer statistics in Japan. Edited by: Kato H, Sobue T, Katanoda K, Saito Y, Tsukuma H, Sakura N, Kitai A. 2008, National Cancer Center, Tokyo.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59 (4): 225-249. 10.3322/caac.20006View ArticlePubMed
- Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007, 8 (9): 773-783. 10.1016/S1470-2045(07)70245-0View ArticlePubMed
- O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348 (11): 994-1004. 10.1056/NEJMoa022457View ArticlePubMed
- Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988, 53 (4): 549-554.View ArticlePubMed
- Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH: BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003, 163 (4): 1255-1260. 10.1016/S0002-9440(10)63485-2PubMed CentralView ArticlePubMed
- Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A: Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol. 2003, 162 (6): 1807-1815. 10.1016/S0002-9440(10)64315-5PubMed CentralView ArticlePubMed
- Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J: Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 1999, 18 (3): 664-674. 10.1093/emboj/18.3.664PubMed CentralView ArticlePubMed
- Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A: AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene. 2006, 25 (35): 4831-4839. 10.1038/sj.onc.1209494View ArticlePubMed
- Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, Marumoto T, Saya H, Horii A: RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005, 65 (7): 2899-2905. 10.1158/0008-5472.CAN-04-3981View ArticlePubMed
- Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A: Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep. 2001, 8 (1): 89-92.PubMed
- Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS: Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol. 1996, 148 (6): 1763-1770.PubMed CentralPubMed
- Yamanaka S, Sunamura M, Furukawa T, Sun L, Lefter LP, Abe T, Yatsuoka T, Fujimura H, Shibuya E, Kotobuki N: Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor-suppressor gene that suppresses angiogenesis. Lab Invest. 2004, 84 (10): 1339-1351. 10.1038/labinvest.3700160View ArticlePubMed
- Lens SM, Voest EE, Medema RH: Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer. 2010, 10 (12): 825-841. 10.1038/nrc2964View ArticlePubMed
- Verdaasdonk JS, Bloom K: Centromeres: unique chromatin structures that drive chromosome segregation. Nat Rev Mol Cell Biol. 2011, 12 (5): 320-332. 10.1038/nrm3107PubMed CentralView ArticlePubMed
- Hirano Y, Ishii K, Kumeta M, Furukawa K, Takeyasu K, Horigome T: Proteomic and targeted analytical identification of BXDC1 and EBNA1BP2 as dynamic scaffold proteins in the nucleolus. Genes Cells. 2009, 14 (2): 155-166. 10.1111/j.1365-2443.2008.01262.xView ArticlePubMed
- Conchon S, Cao X, Barlowe C, Pelham HR: Got1p and Sft2p: membrane proteins involved in traffic to the Golgi complex. EMBO J. 1999, 18 (14): 3934-3946. 10.1093/emboj/18.14.3934PubMed CentralView ArticlePubMed
- Valentine MT, Gilbert SP: To step or not to step? How biochemistry and mechanics influence processivity in Kinesin and Eg5. Curr Opin Cell Biol. 2007, 19 (1): 75-81. 10.1016/j.ceb.2006.12.011PubMed CentralView ArticlePubMed
- Gao S, Alarcon C, Sapkota G, Rahman S, Chen PY, Goerner N, Macias MJ, Erdjument-Bromage H, Tempst P, Massague J: Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol Cell. 2009, 36 (3): 457-468. 10.1016/j.molcel.2009.09.043PubMed CentralView ArticlePubMed
- Giubettini M, Asteriti IA, Scrofani J, De Luca M, Lindon C, Lavia P, Guarguaglini G: Control of Aurora-A stability through interaction with TPX2. J Cell Sci. 2011, 124 (Pt 1): 113-122.PubMed CentralView ArticlePubMed
- Wysocka J, Swigut T, Milne TA, Dou Y, Zhang X, Burlingame AL, Roeder RG, Brivanlou AH, Allis CD: WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell. 2005, 121 (6): 859-872. 10.1016/j.cell.2005.03.036View ArticlePubMed
- Addepalli MK, Ray KB, Kumar B, Ramnath RL, Chile S, Rao H: RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther. 2010, 17 (3): 352-359. 10.1038/gt.2009.155View ArticlePubMed
- Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, Cao X, Wang L, Gao H, Zhu M: ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS One. 2011, 6 (3): e17794- 10.1371/journal.pone.0017794PubMed CentralView ArticlePubMed
- Liu M, Yu H, Huo L, Liu J, Li M, Zhou J: Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor. Biochem Pharmacol. 2008, 76 (2): 169-178. 10.1016/j.bcp.2008.04.018View ArticlePubMed
- Li B, Qi XQ, Chen X, Huang X, Liu GY, Chen HR, Huang CG, Luo C, Lu YC: Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. Brain Res. 2010, 1352: 200-207.View ArticlePubMed
- Mattioni T, Hume CR, Konigorski S, Hayes P, Osterweil Z, Lee JS: A cDNA clone for a novel nuclear protein with DNA binding activity. Chromosoma. 1992, 101 (10): 618-624. 10.1007/BF00360539View ArticlePubMed
- Sun CT, Lo WY, Wang IH, Lo YH, Shiou SR, Lai CK, Ting LP: Transcription repression of human hepatitis B virus genes by negative regulatory element-binding protein/SON. J Biol Chem. 2001, 276 (26): 24059-24067. 10.1074/jbc.M101330200View ArticlePubMed
- Ahn EY, Yan M, Malakhova OA, Lo MC, Boyapati A, Ommen HB, Hines R, Hokland P, Zhang DE: Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci U S A. 2008, 105 (44): 17103-17108. 10.1073/pnas.0802696105PubMed CentralView ArticlePubMed
- Sharma A, Takata H, Shibahara K, Bubulya A, Bubulya PA: Son is essential for nuclear speckle organization and cell cycle progression. Mol Biol Cell. 2010, 21 (4): 650-663. 10.1091/mbc.E09-02-0126PubMed CentralView ArticlePubMed
- Ahn EY, DeKelver RC, Lo MC, Nguyen TA, Matsuura S, Boyapati A, Pandit S, Fu XD, Zhang DE: SON controls cell-cycle progression by coordinated regulation of RNA splicing. Mol Cell. 2011, 42 (2): 185-198. 10.1016/j.molcel.2011.03.014PubMed CentralView ArticlePubMed
- Leser GP, Fakan S, Martin TE: Ultrastructural distribution of ribonucleoprotein complexes during mitosis. snRNP antigens are contained in mitotic granule clusters. Eur J Cell Biol. 1989, 50 (2): 376-389.PubMed
- Prasanth KV, Sacco-Bubulya PA, Prasanth SG, Spector DL: Sequential entry of components of the gene expression machinery into daughter nuclei. Mol Biol Cell. 2003, 14 (3): 1043-1057. 10.1091/mbc.E02-10-0669PubMed CentralView ArticlePubMed
- Bubulya PA, Prasanth KV, Deerinck TJ, Gerlich D, Beaudouin J, Ellisman MH, Ellenberg J, Spector DL: Hypophosphorylated SR splicing factors transiently localize around active nucleolar organizing regions in telophase daughter nuclei. J Cell Biol. 2004, 167 (1): 51-63. 10.1083/jcb.200404120PubMed CentralView ArticlePubMed
- Lamond AI, Spector DL: Nuclear speckles: a model for nuclear organelles. Nat Rev Mol Cell Biol. 2003, 4 (8): 605-612. 10.1038/nrm1172View ArticlePubMed
- Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010, 464 (7291): 1067-1070. 10.1038/nature08956PubMed CentralView ArticlePubMed
- Kuboki Y, Shiratori K, Hatori T, Fujita I, Kimijima A, Yamamoto M, Kobayashi M, Furukawa T: Association of epidermal growth factor receptor and mitogen-activated protein kinase with cystic neoplasms of the pancreas. Mod Pathol. 2010, 23 (8): 1127-1135. 10.1038/modpathol.2010.97View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.